Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Hillstream BioPharma, Inc. HILS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Hillstream BioPharma, Inc. (HILS) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.

HILS Analyst Ratings

Hold
1
Ratings
1 Hold
Based on 1 analysts giving stock ratings to Hillstream BioPharma, Inc. in the past 3 months
Rating breakdown
Hold
1 100%
0%
Buy
0 analysts
100%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 PALI
PALI
Palisade Bio, Inc.
$2.06
+3.52%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 KPRX
KPRX
Kiora Pharmaceuticals, Inc.
$2.44
-0.33%
 APGN
APGN
Apexigen, Inc.
$0.39
+8.48%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 QNRX
QNRX
Quoin Pharmaceuticals, Ltd.
$6.30
+6.42%
 CDIO
CDIO
Cardio Diagnostics Holdings, Inc.
$1.92
+2.13%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message